Flagship Ventures Names Daniel McIntyre Partner

Industry Veteran Assumes new position to lead strategic communication

CAMBRIDGE, Mass., June 29, 2016 -- Flagship Ventures today announced the appointment of Daniel McIntyre to the position of Partner, Strategic Communication. In this new role, he is responsible for communication for Flagship's growing organization as well as for its expanding ecosystem of internally generated start-up companies.

"Flagship is undergoing significant growth and evolution, as we create pioneering companies in the service of human health and sustainability," said Noubar Afeyan, Ph.D., the founder, managing partner and CEO of Flagship Ventures. "Dan's decades of experience in a wide range of biotech and health care environments will be invaluable in setting and executing our communication strategy."

"As the innovator in the field of scientific entrepreneurship, Flagship has created a rare community of academic collaborators, financing and business partners, portfolio companies, and a unique ecosystem of science innovation," said McIntyre. "I'm delighted to have the opportunity and challenge to tell an ever-evolving and compelling story that reflects the nature and value of Flagship's pioneering work."

Dan McIntyre has worked with Flagship since leaving Biogen at the end of 2015, where he was Senior Vice President of Corporate Affairs since 2011. He brings decades of experience in health care public affairs, at the point where communications, public policy and issues management intersect. His expertise includes pharmaceuticals, biologicals and biotechnology and diagnostics and providers. In addition to Biogen, he held the top global position in communications and/or public policy at Wyeth, Pharmacia, and Bayer Pharmaceutical Division. He was also managing director of the health care practices at the communication agencies Fleishman-Hillard and Hill+Knowlton Strategies.

McIntyre's experience in public and government affairs on high-profile issues covers medical product safety and supply; screening and access to therapies in at-risk communities; conduct and reimbursement of clinical trials in the U.S. and developing countries; patient advocacy; and pricing of pharmaceutical and biotechnology therapies. He was a member of Roche's first national accounts marketing organization, specializing in health economics and third-party coverage for antibiotics, oncology therapies and patient care under clinical trials.

About Flagship

Flagship Ventures creates and develops pioneering companies through its unique science-based innovation platform. With $1.4 billion in capital under management across five funds, its team of scientist-entrepreneurs have used hypothesis-driven experimentation to make innovations that tackle the world's biggest challenges in human health, sustainable agriculture and renewable energy. Working as scientific co-founders, as well as business partners, Flagship's team explores hundreds of venture hypotheses, refining and perfecting those few that underpin the market-disrupting companies of the future.

Flagship's health care companies are developing breakthrough medicines to cure diseases and enhance quality of life for patients around the world. In sustainability, it is working to dramatically advance the state of agriculture, nutrition, clean water and renewable energy. Flagship's current portfolio includes Agios (NASDAQ: AGIO), Seres Therapeutics (NASDAQ: MCRB), T2 Biosystems (NASDAQ: TTOO), Editas Medicine (NASDAQ: EDIT), Syros Pharmaceuticals (NASDAQ: SYRS), as well as private companies including Moderna Therapeutics, Indigo Agriculture, Axcella Health. The firm has established strategic innovation partnerships with market leaders AstraZeneca, Merck, Bayer CropScience and Nestle Health Science. Since its founding in 2000, Flagship has conceived and launched more than 40 first-in-class companies through its VentureLabs™ innovation foundry; it has financed and developed another 45 best-in-class companies working with collaborators and academic innovations.